Essrani Rajesh, Berger Andrea
Internal Medicine, Geisinger Medical Center, Danville, USA.
Internal Medicine, Lehigh Valley Health Network, Allentown, USA.
Cureus. 2020 May 22;12(5):e8237. doi: 10.7759/cureus.8237.
Background & aims Celiac disease (CD) is a multisystem disorder triggered by dietary gluten in genetically predisposed individuals that may affect any organ system, including the liver. We evaluated a change in patient model for end-stage liver disease (MELD)-Na and albumin level from the time of celiac disease diagnosis to six months later, after implementing a gluten-free diet. Methods A retrospective study was conducted from January 1, 2006, to June 30, 2018. CD was diagnosed based on celiac antibodies and/or histopathological data. MELD-Na and albumin were calculated at the start of the gluten-free diet and six months later. Additional variables like gender, ethnicity, serum IgA level, serum IgG level, human leukocyte antigen (HLA) type, and markers of end-stage liver disease were collected. Descriptive statistics, including means, were reported with the standard deviation for the continuous variables along with frequencies and percentages for all categorical variables. Results A total of 18 patients (55.6% male) were identified as having both cirrhosis and CD. The mean age at the time of celiac diagnosis was 53.6, and 94.4% were Caucasian. CD was diagnosed using celiac antibodies (100%) and histopathological data (44.4%). Most common celiac antibodies include anti-tissue transglutaminase antibodies (77.8%). End-stage liver disease markers like abdominal ascites (55.6%), variceal bleed (50.0%), acute or chronic kidney injury (16.7%), hepatocellular carcinoma (HCC) (11.1%), hepatic encephalopathy (HE) (50.0%), spontaneous bacterial peritonitis (SBP) (5.6%), and liver transplant (0.0%) were seen. The mean baseline MELD-Na score was 11.8, and albumin was 3.5 at the time of celiac diagnosis and mean MELD-Na was 11.8, and albumin was 3.5 six months after a gluten-free diet. Conclusion It is difficult to conclude any exact relationship between change in MELD-Na score after gluten-free diet, but an improving trend is noted in patients with higher MELD-Na score such as 17 or higher. There is no change or worsening of MELD-Na score in patients with lower MELD-Na score. There was no change in mean MELD-Na and albumin level after gluten-free diet.
背景与目的 乳糜泻(CD)是一种多系统疾病,由遗传易感性个体摄入膳食麸质引发,可能影响包括肝脏在内的任何器官系统。我们评估了在实施无麸质饮食后,从乳糜泻诊断时到六个月后患者的终末期肝病模型(MELD)-Na和白蛋白水平的变化。
方法 进行了一项回顾性研究,时间跨度为2006年1月1日至2018年6月30日。根据乳糜泻抗体和/或组织病理学数据诊断CD。在开始无麸质饮食时和六个月后计算MELD-Na和白蛋白。收集了其他变量,如性别、种族、血清IgA水平、血清IgG水平、人类白细胞抗原(HLA)类型和终末期肝病标志物。对于连续变量,报告包括均值在内的描述性统计数据以及标准差,对于所有分类变量,报告频率和百分比。
结果 共确定18例患者(55.6%为男性)同时患有肝硬化和CD。乳糜泻诊断时的平均年龄为53.6岁,94.4%为白种人。使用乳糜泻抗体(100%)和组织病理学数据(44.4%)诊断CD。最常见的乳糜泻抗体包括抗组织转谷氨酰胺酶抗体(77.8%)。观察到终末期肝病标志物,如腹水(55.6%)、静脉曲张出血(50.0%)、急性或慢性肾损伤(16.7%)、肝细胞癌(HCC)(11.1%)、肝性脑病(HE)(50.0%)、自发性细菌性腹膜炎(SBP)(5.6%)和肝移植(0.0%)。乳糜泻诊断时的平均基线MELD-Na评分为11.8,白蛋白为3.5,无麸质饮食六个月后平均MELD-Na为11.8,白蛋白为3.5。
结论 难以确定无麸质饮食后MELD-Na评分变化之间的确切关系,但在MELD-Na评分较高(如17或更高)的患者中观察到改善趋势。MELD-Na评分较低的患者中MELD-Na评分无变化或恶化。无麸质饮食后平均MELD-Na和白蛋白水平无变化。